USF study confirms Egyptians drank hallucinogenic cocktails in ancient rituals

New paper’s findings reveal a mix of psychedelic drugs, body fluids and alcohol likely used for fertility rituals

University of South Florida

 

image: 

University of South Florida scholar Davide Tanasi holds a 3D-generated replica of the Egyptian Bes mug.

view more 

Credit: Cassidy Delamarter

TAMPA, Fla. (Nov. 15, 2024) – A University of South Florida professor found the first-ever physical evidence of hallucinogens in an Egyptian mug, validating written records and centuries-old myths of ancient Egyptian rituals and practices. Through advanced chemical analyses, Davide Tanasi examined one of the world’s few remaining Egyptian Bes mugs.

Such mugs, including the one donated to the Tampa Museum of Art in 1984, are decorated with the head of Bes, an ancient Egyptian god or guardian demon worshiped for protection, fertility, medicinal healing and magical purification. Published Wednesday in Nature’s Scientific Reports, the study sheds light on an ancient Egyptian mystery: The secret of how Bes mugs were used about 2,000 years ago.

“There’s no research out there that has ever found what we found in this study,” Tanasi said. “For the first time, we were able to identify all the chemical signatures of the components of the liquid concoction contained in the Tampa Museum of Art’s Bes mug, including the plants used by Egyptians, all of which have psychotropic and medicinal properties.”

The presence of Bes mugs in different contexts over a long period of time made it extremely difficult to speculate on their contents or roles in ancient Egyptian culture.

“For a very long time now, Egyptologists have been speculating what mugs with the head of Bes could have been used for, and for what kind of beverage, like sacred water, milk, wine or beer,” said Branko van Oppen, curator of Greek and Roman art at the Tampa Museum of Art. “Experts did not know if these mugs were used in daily life, for religious purposes or in magic rituals.”

Several theories about the mugs and vases were formulated on myths, but few of them were ever tested to reveal their exact ingredients until the truth was extracted layer by layer.

Tanasi, who developed this study as part of the Mediterranean Diet Archaeology project promoted by the USF Institute for the Advanced Study of Culture and the Environment, collaborated with several USF researchers and partners in Italy at the University of Trieste and the University of Milan to perform chemical and DNA analyses. With a pulverized sample from scraping the inner walls of the vase, the team combined numerous analytical techniques for the first time to uncover what the mug last held.

The new tactic was successful and revealed the vase had a cocktail of psychedelic drugs, bodily fluids and alcohol – a combination that Tanasi believes was used in a magical ritual reenacting an Egyptian myth, likely for fertility. The concoction was flavored with honey, sesame seeds, pine nuts, licorice and grapes, which were commonly used to make the beverage look like blood.

“This research teaches us about magic rituals in the Greco-Roman period in Egypt,” Van Oppen said. “Egyptologists believe that people visited the so-called Bes Chambers at Saqqara when they wished to confirm a successful pregnancy because pregnancies in the ancient world were fraught with dangers. So, this combination of ingredients may have been used in a dream-vision inducing magic ritual within the context of this dangerous period of childbirth.”

“Religion is one of the most fascinating and puzzling aspects of ancient civilizations,” Tanasi said. “With this study, we’ve found scientific proof that the Egyptian myths have some kind of truth and it helps us shed light on the poorly understood rituals that were likely carried out in the Bes Chambers in Saqqara, near the Great Pyramids at Giza.”

Close-up image of a 3-D replica of the Egyptian Bes mug used in the study.

Credit

Cassidy Delamarter

The Bes mug is on display now at the Tampa Museum of Art and can be viewed in the exhibition, “Prelude: An Introduction to the Permanent Collection.” View a 3D model of the Bes mug produced by the USF Institute for Digital Exploration.

###

Gathering a sample of the Bes [VIDEO] | 

Univeristy of South Florida scholar Davide Tanasi gathers a sample from the Bes mug.

3-D scanning the Bes mug [VIDEO] | 

University of South Florida scholar Davide Tanasi creates a 3-D replica of the Egyptian Bes mug used in the study.

ty of South Florida scholar Davide Tanasi creates a 3-D replica of the Egyptian Bes mug used in the study.

University of South Florida scholar Davide Tanasi creates a 3-D replica of the Egyptian Bes mug used in the study.

Journal

Scientific Reports

Method of Research

Observational study

Subject of Research

People

Article Title

Multianalytical investigation reveals psychotropic substances in a ptolemaic Egyptian vase

Article Publication Date

13-Nov-2024

 

More than 5 million Americans would be eligible for psychedelic therapy, study finds

As the FDA reviews psilocybin-assisted therapy, Emory’s real-world analysis depicts the public health demand and economic impact based on medical eligibility

Emory Health Sciences

 

image: 

Fayzan Rab, MD candidate, psychedelic researcher, and lead author of the study

view more 

Credit: Emory University

Acupuncture. Ketamine infusions. “Electroshock” or electroconvulsive therapy. The existing treatment options for those diagnosed with Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD), may sometimes feel daunting or expensive alternatives to medication. However, a groundbreaking study from Emory University demonstrates how psilocybin-assisted therapy could impact more than 5 million people in the U.S. pending approval from the FDA.

The findings highlight both the national need for therapies featuring psilocybin, the active ingredient in hallucinogenic mushrooms, as well as the considerations that elected officials, insurance companies, and public health agencies would need to be aware of to successfully roll-out access to psilocybin-assisted therapy (PSIL-AT). 

In the study, researchers used national data from the existing pool of people being treated for MDD and TRD, and applied exclusionary criteria based on comorbidities, such as mania, heart failure, and diabetes, to rule out those who would be medically ineligible for the therapy. These findings indicate that anywhere from 56 to 62% of the individuals being treated for MDD and TRD— roughly 5.1 to 5.6 million people—would be eligible for PSIL-AT and could benefit from it.

“This information is significant because much of the current focus on psychedelic therapies is about its efficacy within clinical trials, and very few people are studying what would be the broader implications of implementing these novel therapeutics,” says Fayzan Rab, lead author of the study and M.D. candidate at Emory University’s School of Medicine. “Our study is one of the first to look at the bigger public health and economic consequences of a world where psilocybin therapy is made more available to Americans.” 

According to Rab, psilocybin-assisted treatment currently has a breakthrough designation with the FDA, meaning that it will expedite a review of the Phase III clinical trial results because of its potential as a therapeutic for depression.

“What is really timely about this research is that it provides a data-driven number that is interpretable to the FDA,” says Rab. “This is how many Americans we think are at stake. I think that will be a meaningful estimate for the FDA to weigh when they consider whether to approve psilocybin for therapeutic use.” 

If approved, private and public insurers such as the Centers for Medicare & Medicaid Services will shape both the demand and the availability of psychedelic therapy. According to the study, almost 20% of the 85 million Medicaid beneficiaries—or 17 million people – are likely to have clinical depression. Therefore, the conditions under which Medicaid might or might not reimburse for psilocybin-assisted therapy will determine the demand.  

A psycho-spiritual model to bring patients to a state of spiritual and mental wellness

An additional prominent attribution to the study is that it is supported by Emory University’s Center for Psychedelics and Spirituality(ECPS), which integrates clinical and research-backed expertise in psychiatry and spiritual health to better understand the therapeutic value of psychedelic medicines. 

George Grant, MDiv, PhD, and co-director of the ECPS, emphasizes that the public health forecast in Rab’s study provides policymakers with an idea of the economic impact, as well as if the treatment will meet the needs of the underserved. 

“Coming to the aid of people who are suffering is very important, and psilocybin-assisted therapy could help people arrive to a place of satisfaction within themselves so that their lives achieve optimal meaning and purpose,” says Grant, also the executive director for Spiritual Health at the Woodruff Health Sciences Center. Regarding the economic impact on the healthcare system, Grant adds, “Psychedelic medicines have promise because the intervention is so fast acting, whereas right now, insurance providers and payers often need to fund the use of antidepressants throughout their lives.” 

Grant is referring to past clinical trials studying the efficacy of psilocybin, which indicate that just one singular 25 mg dose of psilocybin is often enough to reduce symptoms of depression—potentially decreasing the financial burden on insurance payers currently funding other interventions. 

“I am glad to be supported by the Center for Psychedelics and Spirituality, which is an academic environment, providing an objective third-party perspective to policymakers, the FDA, and public health agencies,” says Rab, emphasizing that the study was not done in conjunction with any pharmaceutical agencies. “I am really hopeful that continued research in the area of psychedelic medicine and therapeutics could benefit the millions of Americans that might qualify for it.” 

CITATION: Rab, Syed Fayzan et al. An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United States. Genomic Press Psychedelics. 13 September 2024.

---

Method of Research

Data/statistical analysis

Subject of Research

Not applicable

Article Title

An estimate of the number of people with clinical depression eligible for psilocybin-assisted therapy in the United States

Canada should be ‘world leader’ on alternative PTSD therapies, veteran says

By Sean Boynton Global News
Posted November 10, 2024

WATCH: After being injured in Canada's longest, most expensive war effort, one veteran created and fundraised an exhibit to help ensure the efforts of those who served — and the memories those who died — aren't forgotten. Mercedes Stephenson explains  

A Canadian Forces veteran who served in Afghanistan says Canada should be a “world leader” on alternative therapies for treating veterans’ post-traumatic stress disorder and other post-combat trauma, including the use of psychedelics.

Retired MCpl. Gordon Hurley says psychedelic treatments such as ketamine and psilocybin, or “magic mushrooms,” can give veterans “a breath of relief” from their trauma or addictions, pointing to his own experience, and is calling for further study and coverage for physician-assisted therapies.

“I really think we’re in a unique position as a country, with such a liberal view on health care and life, that we should be able to be a world leader in providing alternative therapies,” he told Mercedes Stephenson in an interview that aired Sunday on The West Block ahead of Remembrance Day.

“We should be doing the same thing with our veterans just how you send us to war. A majority of the time we’re saying, ‘Send me, send me.’ We can do the same thing with these types of treatments.”

Hurley deployed to Afghanistan in the summer of 2008, just 15 months after joining the military and completing basic training. He was injured by an improvised explosive device but returned to the battlefield just three weeks after surgery.

2:21

Nova Scotia company to examine magic mushrooms as PTSD treatment



More than 40,000 Canadians served in Afghanistan, many on multiple tours during the 20-year global War on Terror, and 165 Canadian Armed Forces members died there.

Many veterans of that war returned to Canada suffering not just from PTSD but also traumatic brain injuries and effects from toxic burn pit exposure, among other traumas.

Research has suggested recent veterans have had a higher rate of mental health and addiction issues compared to older veterans and the overall Canadian population.

Veterans Affairs Canada is conducting research and clinical trials into the use of ketamine as a treatment for traumatic brain injuries and depression, but has yet to launch a similar project on psilocybin. Independent studies have been launched across Canada in recent years into psychedelic treatments

A Senate committee report last December urged the federal government to “immediately” conduct a “major research program” into how psychedelics can help veterans suffering from PTSD. The report said research already exists into the effectiveness of such treatments and warned Canada is falling behind other countries in studying them.

The United States has funded research into psychedelic treatments for veterans, but the U.S. FDA this year rejected an approval for MDMA treatment, calling for further study.

Briefing notes prepared for the veterans affairs minister last year say the department only provides financial coverage for treatments that are supported by solid research, and says approved psychological and psychiatric treatments are the “first-line evidence-based” approach to treating PTSD and other mental issues.

2:01

Psychedelics approved for medical use in Canada

“Western treatment is completely fine,” Hurley said. “There’s nothing wrong with prescription drugs or SSDIs (antidepressants), whatever is going to work to get that person off the ledge is worth it. But there are other treatment options.”

Hurley said he travels to Mexico to receive treatment through psychedelics through a clinic run by Canadian doctors, and touted their effectiveness.

Besides psychedelics, Hurley also pointed to a treatment known as stellate ganglion block, which numbs nerves in the neck and “basically resets your nervous system,” he said. The treatment has been studied at multiple Canadian hospitals and universities and has been called “miraculous” in treating PTSD.

“To get that initial breath and that initial pause where they don’t have the cravings for their addiction, or they don’t have the annoyances of trauma, of post-traumatic stress, of perhaps being too freaked out to go into public spaces or noises and all these other detriments to the veteran’s life … we could be fixing with different types of treatment,” he said.

Hurley said the government should particularly cover assisted treatment programs that allow doctors to work with patients and ensure veterans are taking the proper treatments and dosages.

“The doctor is going to have specific training to deal with psychedelics and how that integrates into a person’s life,” he said.

“We’re so new to it. It’s not anyone’s fault, but we should really be ahead of the curve on this.”

Psychedelic therapy provides hope for veterans

Story by Maya Goldman


Psychedelic therapy provides hope for veterans

Veterans are campaigning to take psychedelic therapy for post-traumatic stress disorder mainstream, despite the Food and Drug Administration's rejection of an ecstasy-based therapy in August.

Why it matters: About 29% of veterans who fought in Afghanistan and Iraq will have PTSD at some point in their lives, according to the Department of Veterans Affairs. Veteran suicide rates are also higher than in the general population.

"The thirst is very palpable among our generation" of veterans for alternative mental health therapies, Allison Jaslow, CEO of Iraq and Afghanistan Veterans of America, told Axios.

Catch up quick: Psychedelics like magic mushrooms, LSD and ecstasy can alter a person's state of mind and cause hallucinations.
It's been nearly impossible to research their effects, because they've been criminalized and classified as controlled substances since 1970.
But interest in psychedelics' potential to treat mental health conditions — particularly in veterans — has grown in recent years.
The FDA in 2017 granted fast-track review of a PTSD treatment that mixes ecstasy with talk therapy.

The VA started funding research into psychedelic therapies this year. Congress also passed bipartisan legislation directing the Pentagon to study the treatments.
In the meantime, more than 1,200 veterans traveled to other countries for psychedelic therapies through one nonprofit alone, said Jesse Gould, founder of that organization, Heroic Hearts Project.

But the FDA in August rejected the therapy it had originally fast-tracked, following an independent review that highlighted concerns like missing safety data and allegations of misconduct in clinical trials.

Zoom in: The decision felt like a major setback to veterans.
"It was emotionally just gut-wrenching, thinking about all of those veterans, and all the other people, for that matter, that were just really counting on being able to access this as a solution for their debilitating PTSD," said Juliana Mercer, a Marine Corps veteran and director at veterans advocacy group Healing Breakthrough.
The FDA rejection pushes mental health progress back years, added Gould, a former Army Ranger. It "indicates to veterans that they are not being listened to and they're not a priority."

Where it stands: Veterans are continuing to work toward broadening access to psychedelic therapies.
State-level action is also picking up. Oregon and Colorado have legalized psychedelic mushrooms for therapeutic use. But Massachusetts voters last week rejected a ballot proposal to legalize psychedelics.

What's next: The company behind the rejected ecstasy-based therapy now has a new acting CEO and chief medical officer, and it announced last month that it will run a new clinical trial on the PTSD treatment.

The VA has reportedly said it would consider funding the trial.
The FDA also fast-tracked review for a psychedelic mushroom therapy, though the company running that trial announced recently that it's delaying a key data release.

The new clinical trials will likely take at least two more years, Mercer predicted.
But the extended timeline means the VA "is going to be more prepared to effectively roll out a psychedelic program," she said. "I'm choosing to look at that as a silver lining."

Smoking toad venom helps veterans with PTSD, addiction, and depression

Allan Rose Hill
Mon Nov 11, 2024
BOING!BOING!


image: Deep Desert Photography/Shutterstock (manipulated)

Zach Skiles is a veteran and clinical psychologist who, informed by his own experiences, is helping other veterans deal with PTSD, depression, and drug addiction. As a researcher with University of California at San Francisco, Skiles leads veterans through psychedelic experiences to help alleviate some of their suffering. The participants are first given ibogaine—a natural stimulant with psychedelic properties found in the West African shrub iboga. After a long "group healing" session, they are administered 5-MeO-DMT, an extremely powerful and short-lasting psychedelic found in the venom of the Sonoran Desert toad. (Both compounds can also be synthesized in a laboratory.) Unfortunately. both of these compounds are illegal in the United States so the veterans must travel to Mexico for the actual treatments. In honor of Veteran's Day, the always-excellent Microdose republished Jan C. Hu's 2021 interview with Skiles:

What aspects of psychedelic therapy might help treat veterans in particular?

In treating PTSD, psychedelics enhance your ability to bring up trauma and simultaneously see it from different angles. Everything feels new, more revelatory and connected. There's the ability to take a step back and experience something in a totally new way.

One of the cooler things about psychedelic assisted therapies is you're not only getting those cognitive pieces, but you're also getting somatic, cathartic experiences at the same time. For people who've experienced sexual assault or combat exposure, you cut off a lot of sensation from your body and reconnecting to it is actually one of the main goals of all therapies. Having that experience along with these cognitive pieces is something that they call a codex condensed experience — it's happening in different constellations of the mind and body[…]

These therapies aren't legal in the U.S. What drove you and other vets to seek out these experiences in Mexico?

There's a bit of desperation; people have to leave the country to be able to get these therapies. These are folks who have spent careers in the U.S. Special Forces, with blast injuries or lesions on their brain. It's a group of folks who have tried every single therapy that's offered in the United States and have come up wanting more. They had to leave the country in order to have a therapeutic experience, and not be arrested for it.

It's important to give guys an ability to have the most up to date therapeutic access, but in the U.S.; it's also important for this to become regulated. We operate in the underground because that's the only place we can do this kind of thing.

Previously:
• FDA denies approval of MDMA-assisted therapy for PTSD
• These psychonauts are in training to take DMT trips that last hours or even days and report back… for science
• 'Please refrain from licking' toads, says National Park Service in unusual warning

 

Healing, spiritual purposes drive many veterans’ use of psychedelics

In survey, 85% of veterans report they benefited from the experience

Ohio State University

COLUMBUS, Ohio – Most U.S. military veterans who have used psychedelics reported in a recent study that they pursued the substances for healing or spiritual exploration, and over 80% said they benefited from the experience – even those who had challenging outcomes.

The survey also indicated many of the veterans would be more likely to seek mental health care, or return to care, at the U.S. Department of Veterans Affairs (VA) if psychedelic-assisted therapy were offered.

Findings from this comprehensive examination of veterans’ experiences with psychedelics can give clinicians a clearer understanding of the veteran community’s expectations and specific needs for mental health care, researchers say.

“Because of all of the complexity that veterans are experiencing and the higher risk they’re at for experiencing not just one, but several mental health and physical health-related challenges, it makes sense that they would be searching for opportunities to address those challenges, especially when they feel like they’re not being met with the current system here in the U.S.,” said lead author Alan Davis, associate professor and director of the Center for Psychedelic Drug Research and Education at The Ohio State University College of Social Work.

The study was published recently in the Journal of Psychoactive Drugs.

The VA estimates that more than 17 U.S. veterans die by suicide each day, according to 2021 data. And studies suggest between 44% and 72% of veterans are highly stressed during the transition from military to civilian life.

The research team, which included veterans, consulted with other past military service members to design a survey examining patterns of psychedelic use, perspectives of those who did and did not report use, and what kinds of benefits and adverse outcomes were associated with veterans’ use of the drugs. Veterans were referred to the survey through online advertisements and communities, email invitations and word of mouth.

“Understanding military veteran culture is crucial for civilian therapists working with this population,” said co-author Mark Bates, a retired U.S. Air Force pilot and clinical psychologist at Sunstone Therapies, a Maryland treatment center researching psychedelic-assisted therapies.

“It’s about avoiding inadvertently undermining the therapeutic relationship and knowing how to use military culture as an effective frame of reference. This is also part of the reason of why we carefully consulted with a team of veteran advisers in the development and validation of the survey questions.”

With veteran advocacy for access to psychedelic-assisted therapy increasing in recent years, Bates said, “There is a really pressing need to explore anything that’s promising for mental health treatment.”

The survey sample consisted of 426 participants categorized into two groups – those who had (217) and had not (209) used psychedelics. Drugs used by veterans included psilocybin (magic mushrooms), LSD, ketamine, MDMA (ecstasy), ayahuasca, ibogaine, 5-MeO-DMT (toad) and peyote/mescaline. The most commonly reported reasons for use were healing or treatment (69%), spiritual exploration (47.5%) or recreation (38.7%).

Compared to veterans who had not used psychedelics, the veterans who had taken the drugs were more likely to be older and had spent more time deployed during their service, and a larger proportion of them reported PTSD, depression and anxiety.

While some participants were alone when they used psychedelics, many reported taking them in spiritual locations or outdoors, with friends, or in medical clinics or retreat centers – both in the United States and abroad.

Overall, participants rated the psychedelic experiences as beneficial whether they considered the experience uniformly positive (88.6%) or endured one or more adverse outcomes (81.3%). The most common adverse outcomes were flashbacks and craving or trying to reduce use of psychedelics. Fewer participants reported being arrested or seeking medical treatment in relation to using the drugs.

Statistical analysis identified a number of factors that lowered the likelihood of having negative outcomes: being older, using psilocybin, having depression or anxiety, obtaining psychedelics from a safe source, being prepared, comfortable and confident during the treatment, and being able to trust, let go and be open to the experience.

“This finding highlights the importance of people in the veteran community knowing that keeping these things in mind prior to use can help set them up for the best possible outcome,” Davis said.

With most psychedelic substances classified as Schedule I drugs under the Controlled Substances Act, the only legal way for most people to access them in the United States currently is in a clinical trial setting. Davis is leading a current psilocybin-assisted therapy study at Ohio State for the treatment of PTSD among military veterans, and Bates and colleagues at Sunstone Therapies have treated many veterans to date.

Finding that surveyed veterans would welcome a chance to access psychedelic-assisted therapy at the VA is an important highlight of the study, the researchers said.

“What’s really exciting about this study and understanding veterans’ interest in psychedelic-assisted therapy is it’s potentially opening up an opportunity to address some of their core challenges head-on,” Davis said. “Veterans are dying by suicide and fleeing the country to find these opportunities in other places, so the message is clear. This needs to be available.”

Additional co-authors were Nathan Sepeda, Adam Levin and Stacey Armstrong of Ohio State; independent researcher Erik Lund; Robert Koffman of Sunstone Therapies; Katinka Hooyer of the Medical College of Wisconsin; and Rachel Yehuda of the Icahn School of Medicine at Mount Sinai.

This work was supported by private donors, the Cammack Family Gift Fund, the Center for Psychedelic Psychotherapy and Trauma Research at the Icahn Medical School, the Johns Hopkins Center for Psychedelic and Consciousness Research, and the CPDRE at Ohio State.

#

---

Journal

Journal of Psychoactive Drugs

DOI

10.1080/02791072.2024.2401977 

Method of Research

Survey

Subject of Research

People

Article Title

The Epidemiology of Psychedelic Use Among United States Military Veterans

 

Mapping the neurocircuit for the acute effects of psychedelics on anxiety

Tata Institute of Fundamental Research

 

image: 

A Novel target for Anti-Anxiety Psychedelic drugs

view more 

Credit: Prepared by CACTUS

Psychedelics have been used in indigenous cultures for centuries, with empirical evidence of their mood and perception altering effects. Recently, there has been a renewal of interest in psychedelics given putative therapeutic effects in psychiatric disorders such as anxiety and depression. However, it has remained a mystery as to how psychedelics actually bring about changes in mood-related behavior. A team of researchers led by Prof. Vidita Vaidya from TIFR Mumbai, in collaboration with research groups from Cornell, Columbia and Yale University mapped the precise part of the brain, and the specific class of neurons within this brain region, that drives the decrease in anxiety caused by acute treatment with the psychedelic DOI.

The psychedelic DOI when administered to rats or mice systemically, decreases anxiety behavior on approach-avoidance behavioral tasks, such as the elevated plus maze and open field test. To precisely pinpoint the part of the brain that responds to DOI and drives this decrease in anxiety behavior, local infusions of the drug into targeted brain regions uncovered a critical role of the ventral hippocampus in mediating this effect of the psychedelic DOI. Further, the study uncovered that the psychedelic DOI targets the serotonin2A receptor in the ventral hippocampus to exert its effects on anxiety. At the same time, the team also ruled out contributions from other brain regions including the prefrontal cortex and amygdala. What was striking is that the ventral hippocampus while vital for the decrease in anxiety evoked by DOI, did not contribute to hallucinations, highlighting that psychedelics target different parts of the brain to drive many behavioral changes.

Electrophysiological studies revealed that the psychedelic DOI increased the firing of parvalbumin-positive, fast-spiking, interneurons in the ventral hippocampus, which express the serotonin2A receptor. This identified the potential cellular trigger through which the psychedelic DOI may reduce anxiety behavior. To behaviorally test this, chemogenetic strategies were used to activate this particular subclass of neurons within the ventral hippocampus in the absence of the psychedelic DOI, which was sufficient to decrease anxiety behavior in animal models. Further, using a genetic knockout mouse model that lacked any serotonin2A receptor in the brain and body, selective restoration of the serotonin2A receptor on parvalbumin neurons was sufficient to reinstate the decline in anxiety that was seen on treatment with the psychedelic DOI in the ventral hippocampus.  Together, using genetic, pharmacological, electrophysiological and behavioral studies, the team identified parvalbumin-positive, fast-spiking, interneurons in the ventral hippocampus as the cellular trigger through which the psychedelic DOI can reduce anxiety.

This provides the first evidence of a clear mapping of the precise neuronal population and brain region targeted by a psychedelic to influence anxiety behavior. Since it also demonstrated that this brain circuit does not evoke altered perception and hallucinations, it opens up the intriguing possibility of using psychedelic-inspired drugs that have therapeutic potential for the treatment of anxiety disorders, whilst not exerting potent hallucinatory effects. 

---

Journal

Neuron

DOI

10.1016/j.neuron.2024.08.016 

Article Title

Ventral hippocampal parvalbumin interneurons gate the acute anxiolytic action of the serotonergic psychedelic DOI

 

Psychedelic drug psilocybin changes brain connectivity to treat body dysmorphic disorder

Columbia University researchers uncover how a single dose of "magic mushrooms" changes brain connectivity to alleviate symptoms of the devastating mental illness

Genomic Press

 

image: 

Whole brain multivariate pattern analysis (MVPA) reveals that seed brain regions including the thalamus [8 -6 8] (yellow), insula [-42 8 -6] (green), inferior parietal lobe (IPL) [-54 -38 38] (red), and ACC [16 34 24] (blue) predicted symptomatic improvement of body dysmorphic disorder (BDD) at one week following a single dose of psilocybin. Using these clusters as seed regions, no further regions were identified. 

view more 

Credit: Xi Zhu, Columbia University, New York, NY

New York, NY - Body dysmorphic disorder (BDD) is a debilitating mental illness characterized by an obsessive preoccupation with perceived flaws in one's physical appearance. Patients with BDD often have distorted self-image, intrusive thoughts, and compulsive behaviors that significantly impair daily functioning and quality of life. Current therapies have limited efficacy, leaving many sufferers without relief.

A new study led by researchers at Columbia University and published in Psychedelics (Genomic Press, New York, USA) provides hope by revealing how the psychedelic drug psilocybin, the active ingredient in "magic mushrooms," may rewirechange connectivity of brain circuitry, potentially aiding in the treatment of this debilitating disorder.

In the pilot trial, eight adults with moderate-to-severe BDD that had not responded to standard treatments received a single 25mg oral dose of psilocybin in a supportive setting. Using cutting-edge functional MRI technology, the scientists scanned the participants' brains one day before and one day after the psilocybin session. Sophisticated pattern analysis techniques were then applied to map changes in brain network connectivity and link them to subsequent clinical outcomes.

The results were striking: Just one day after psilocybin administration, the patients exhibited increased connectivity both within a network governing executive functions, and between this network and others involved in processing emotionally salient stimuli and self-referential thinking. Notably, those who showed the greatest strengthening of these neural connections also experienced the most improvement in BDD symptoms one week later.

While preliminary, the findings align with a growing body of evidence indicating that psychedelic compounds like psilocybin can promote mental health by enhancing the brain's capacity for flexibility and integration. By facilitating communication within and between brain networks that are often dysregulated in psychiatric disorders, psilocybin may help restore more adaptive cognitive and emotional functioning.

As the first study of psilocybin in a BDD population, the trial was small and lacked a placebo control. The researchers caution that larger, placebo-controlled studies are needed to verify the efficacy and durability of the treatment. Still, the robust brain-behavior relationships uncovered bode well for the ongoing development of psilocybin therapy.

The peer-reviewed study, "Single-Dose Psilocybin Alters Resting State Functional Networks in Patients with Body Dysmorphic Disorder," will be published on September 24, 2024, in Psychedelics. It is freely available online at https://pp.genomicpress.com/aop/.

About Psychedelics – Psychedelics: The Journal of Psychedelic Pharmacology (ISSN: 2997-2671) is a peer-reviewed journal published by Genomic Press, New York. The journal is exclusively dedicated to the latest advancements in the realm of psychedelic substances and their potential therapeutic uses. Psychedelics embraces the full spectrum of research, from fundamental investigations to cutting-edge clinical studies and welcomes diverse perspectives and contributions, advancing the understanding of psychedelic compounds.

Contact: Chen Zhang, Columbia University: Chen.Zhang@nyspi.columbia.edu

---

Method of Research

Experimental study

Subject of Research

People

Article Title

Single-Dose Psilocybin Alters Resting State Functional Networks in Patients with Body Dysmorphic Disorder

Article Publication Date

24-Sep-2024

COI Statement

Dr. Schneier has received research support from Compass Pathways, Otsuka, Vistagen, and NIMH, royalties from UptoDate, Cambridge University Press, and Guilford Press, and served as consultant to Receptor Life and PureTech. Dr. Hellerstein has received research support from Compass Pathways, Relmada, Intracellular Therapies, Beckley Foundation, serves on the scientific advisory board for Reset Pharmaceuticals and has received royalties from Johns Hopkins University Press and Columbia University Press. Dr. Feusner receives research support from the NIMH, NIBIB, and the Klarman Family Foundation and serves as a consultant to NOCD, Inc. Drs. Wheaton, Zhu, and Ms. Chen and Ms. Gomez have no financial relationships to report. This research was supported by a grant from Compass Pathways PLC, United Kingdom. Compass supplied materials and participated in formulating the outline of the study but had no role in study selection or interpretation of the evidence.

Psilocybin may curb mental illness linked to eating disorders

By Dennis Thompson, 

Sept. 24, 2024 

HealthDay News


Psilocybin could help people suffering from a mental health problem that can lead to eating disorders, a new study suggests. Photo by Adobe Stock/HealthDay News

Psilocybin could help people suffering from a mental health problem that can lead to eating disorders, a new study suggests.

Psilocybin, the active chemical in "magic" mushrooms, significantly reduced symptoms in people with body dysmorphic disorder (BDD), researchers reported Tuesday in the journal Psychedelics.

BDD causes an obsessive preoccupation with perceived flaws in one's physical appearance, and is frequently tied to eating disorders and other unhealthy behaviors, researchers said.

For this pilot trial, eight people with hard-to-treat BDD received a single 25-milligram dose of psilocybin.

Brain scans showed that the psilocybin treatment increased levels in connectivity between different brain regions related to emotional processing, cognitive activity and feelings and thoughts about oneself.

People who had the greatest strengthening in these connections experienced the most improvement in their BDD symptoms within a week, results show.

The findings "align with a growing body of evidence indicating that psychedelic compounds like psilocybin can promote mental health by enhancing the brain's capacity for flexibility and integration," concluded the research team led by Chen Zhang, a research assistant with the New York State Psychiatric Institute.

"By facilitating communication within and between brain networks that are often dysregulated in psychiatric disorders, psilocybin may help restore more adaptive cognitive and emotional functioning," the research team said in a journal news release.
Advertisement

However, more studies in larger groups of people with BDD are needed to verify the effectiveness of the treatment and how long it will last, the researchers noted.

More information

Johns Hopkins Medicine has more on psilocybin therapy.

Copyright © 2024 HealthDay. All rights reserved.